Medicare IVIG Access Enhancement Act of 2023

The Medicare IVIG Access Enhancement Act of 2023, also known as Bill 118 hr 5818, aims to improve access to Intravenous Immunoglobulin (IVIG) for Medicare beneficiaries. IVIG is a treatment used for various autoimmune and inflammatory conditions, but access to this treatment can be limited due to high costs and administrative barriers.

This bill seeks to address these issues by establishing a demonstration project that would provide coverage for IVIG for Medicare beneficiaries in both inpatient and outpatient settings. The goal of this project is to evaluate the effectiveness of providing coverage for IVIG and determine the impact on patient outcomes and healthcare costs.

Additionally, the bill includes provisions to streamline the process for prescribing and administering IVIG, as well as measures to improve coordination of care for patients receiving this treatment. It also calls for increased education and training for healthcare providers on the use of IVIG. Overall, the Medicare IVIG Access Enhancement Act of 2023 aims to improve access to IVIG for Medicare beneficiaries, with the ultimate goal of improving patient outcomes and reducing healthcare costs.